BioCatch

BioCatch is valued at $1B.

Investor information for BioCatch is not publicly available at this time.

No public funding round data is currently available for BioCatch.

BioCatch has approximately 100-500 employees.

BioCatch provides behavioural biometrics and fraud prevention AI that analyses how users physically interact with digital devices — mouse movements, typing cadence, touch pressure, and navigation patterns — to authenticate genuine users and detect account takeover, social engineering, and application fraud in real time during banking and financial transactions. The Tel Aviv company processes behavioural signals from hundreds of millions of user sessions monthly, building individual profiles that flag deviations indicating fraud.\n\nThe company raised approximately $213 million in venture funding including a Series D led by Tiger Global, reaching a valuation exceeding $1 billion. BioCatch counts over 30 tier-one banks globally among its clients including American Express, NatWest, and Lloyds Banking Group, with deployments protecting online banking and mobile banking sessions from fraud that bypasses traditional authentication controls. The platform is particularly effective against malware-assisted fraud and social engineering scams where the genuine account holder is unknowingly manipulated.\n\nBioCatch competes in the behavioural biometrics and fraud intelligence market alongside ThreatMetrix (now LexisNexis Risk Solutions), Sift, and Sardine, as well as traditional fraud management platforms from FICO and SAS. Its differentiation is the depth of its behavioural feature engineering from passive interaction signals that do not require active user participation, creating a fraud layer that operates continuously without adding friction to legitimate user journeys. The growing prevalence of authorised push payment fraud and social engineering attacks in European banking has expanded the relevant use case for BioCatch beyond traditional account takeover detection.